Becton Dickinson stock holds after recent results

Becton Dickinson and Company (ISIN US0718131099) stays centered on its latest reported numbers, including fiscal 2025 revenue of $20.2 billion, adjusted diluted EPS of $12.44, and adjusted free cash flow of $2.8 billion. The company also reported fourth-quarter fiscal 2025 revenue of $5.9 billion and adjusted diluted EPS of $3.68, according to its latest financial reporting.

Fiscal 2025 sets the frame

The fiscal 2025 revenue of $20.2 billion provides the main anchor for Becton Dickinson stock, because it shows the scale of the business across medical devices and diagnostics. Adjusted free cash flow of $2.8 billion for fiscal 2025 adds another useful reference point for investors tracking earnings quality and cash generation.

The quarterly comparison matters too. Fourth-quarter fiscal 2025 revenue of $5.9 billion and adjusted diluted EPS of $3.68 give a narrower read on execution than the full-year figures, and they show how the company ended the year.

Margins and cash flow matter

Becton Dickinson reported adjusted gross margin of 49.7% for fiscal 2025, which helps explain how the group converted sales into profit. Adjusted operating margin of 25.8% for fiscal 2025 and adjusted diluted EPS of $12.44 for the same year round out the picture.

Those numbers are useful because they connect scale, profitability, and cash conversion in one reporting cycle. For a healthcare supplier with a broad installed base, the combination of $20.2 billion revenue and $2.8 billion free cash flow is often more informative than any single line item.

What the latest quarter showed

Fourth-quarter fiscal 2025 revenue of $5.9 billion set the short-term pace, while adjusted diluted EPS of $3.68 showed that profitability remained intact into year-end. The quarter also helps frame the full-year result, since the company moved from quarterly delivery to a fiscal 2025 base of $20.2 billion in sales.

That comparison is the key one in this article: the company finished fiscal 2025 with a $20.2 billion top line versus $5.9 billion in the fourth quarter alone, a reminder of the seasonal and recurring nature of its business mix. For readers tracking Becton Dickinson stock, the reported margin profile is as important as the revenue headline.

Products and procedures

Becton Dickinson's product portfolio spans medication delivery, specimen management, diagnostics, and surgical solutions, which gives the company several ways to convert hospital and lab demand into revenue. That diversity matters when evaluating whether the fiscal 2025 revenue base of $20.2 billion is broad enough to withstand swings in any single line.

The business mix also helps explain why cash flow remains a central metric. A company that generated $2.8 billion in adjusted free cash flow in fiscal 2025 can fund investment, debt reduction, and shareholder returns with more flexibility than a slower cash generator.

Closing at the latest base

As a stock-market reference point, Becton Dickinson stock is framed here by its fiscal 2025 results rather than a live quote. The latest evidenced market value in this article is the companys reported revenue and profit base, which remains the cleanest dated anchor for the shares in the absence of a current price feed.